3.165USD-1.56%Mkt Cap: 225.37M USDP/E: —Last update: 2026-06-01
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen re…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap225.37M USD
Enterprise Value76.74M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-104.08M USD
Revenue/Share—
Last Price3.165 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees108
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.88
PEG—
EV/EBITDA-0.72
EV/Revenue—
P/S—
P/B0.74
EPS (TTM)-1.35
EPS (Forward)-1.73
52W Range
1.63076% of range3.650
52W High3.650 USD
52W Low1.630 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-33.33%
ROA-25.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.70M USD
CapEx (TTM)1.21M USD
FCF Margin—
FCF Yield-25.46%
Net Debt-155.43M USD
Net Debt/EBITDA1.47
Balance Sheet
Debt/Equity0.24
Current Ratio12.96
Quick Ratio12.75
Book Value/Sh4.394 USD
Cash/Share3.221 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)11.20 USD
Target Range9.000 USD – 16.00 USD
# Analysts5
Ownership
Shares Out.71.55M
Float60.45M
Insiders4.88%
Institutions80.45%
Short Interest
Short Ratio4.7d
Short % Float9.03%
Short % Out.7.22%
Shares Short5.16M
Short (prev mo.)5.41M
Technical
SMA 502.694 (+17.5%)
SMA 2002.261 (+40.0%)
Beta0.89
S&P 52W Chg27.94%
Avg Vol (30d)813.62K
Avg Vol (10d)586.89K
Technical Indicators
RSI (14)59.4
MACD0.0999
MACD Signal0.0824
MACD Hist.+0.0175
BB Upper3.458 USD
BB Middle3.033 USD
BB Lower2.609 USD
BB Width28.01%
ATR (14)0.2141 USD
Vol Ratio (20d)0.34x